Breakthrough in Understanding Multiple Sclerosis: Epstein Barr Virus and Immune Evasion
A significant discovery has been made in the field of multiple sclerosis (MS) research, shedding light on the mechanisms that trigger the onset of this debilitating disease. According to a study conducted by the Department of Neuroscience at the Istituto Superiore di Sanità, B lymphocytes infected with the Epstein Barr virus (EBV) play a crucial role in blocking the immune response in the central nervous system. This process, mediated by the expression of a specific protein, allows the cascade of events leading to MS to begin.
The Role of Epstein Barr Virus in MS
EBV is a common virus that infects B lymphocytes, a type of white blood cell. While EBV infection is generally asymptomatic, research has shown that it can cause damage to the myelin sheath surrounding nerve fibers, leading to impaired nerve impulse transmission. Daniela Merlo, head of the Neuroscience department at the ISS, explains that “recent studies highlight how it is precisely the B lymphocytes infected by EBV that cause damage to the myelin sheath, making it difficult or even preventing the effective transmission of nerve impulses from the central nervous system to the periphery.”
Immune Evasion and MS Progression
The study, which analyzed autopsy brain tissue from individuals with MS, found that infected B lymphocytes are able to persist in the brain and promote disease progression. This is due to a mechanism called “immune evasion,” where the infected B cells are protected from the defensive attack of the immune system. As Barbara Serafini notes, “once these infected B lymphocytes have entered the brain tissue, they are not removed efficiently by the T lymphocytes, the white blood cells responsible for removing cells infected by viruses and bacteria.” This immune evasion mechanism has been described in certain tumors and is now being targeted by immunotherapies.
Implications for Future Therapies
The discovery of this mechanism opens up new avenues for the development of targeted therapies aimed at eliminating infected cells from brain tissue. By “flushing out” these cells, researchers hope to prevent the progression of MS and potentially even reverse some of the damage caused by the disease. As Serafini concludes, “the study opens new perspectives for the development of therapies increasingly aimed at targeting and eliminating infected cells in order to halt disease progression.” For more information on this breakthrough, visit Here